Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Common Equity (2020 - 2025)

Oncology Institute's Common Equity history spans 6 years, with the latest figure at -$15.7 million for Q4 2025.

  • For Q4 2025, Common Equity fell 538.01% year-over-year to -$15.7 million; the TTM value through Dec 2025 reached -$15.7 million, down 538.01%, while the annual FY2025 figure was -$15.7 million, 538.01% down from the prior year.
  • Common Equity reached -$15.7 million in Q4 2025 per TOI's latest filing, down from -$12.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $132.0 million in Q1 2022 to a low of -$15.7 million in Q4 2025.
  • Average Common Equity over 5 years is $56.3 million, with a median of $49.0 million recorded in 2021.
  • Peak YoY movement for Common Equity: skyrocketed 364.01% in 2021, then crashed 538.01% in 2025.
  • A 5-year view of Common Equity shows it stood at $104.2 million in 2021, then increased by 18.26% to $123.2 million in 2022, then tumbled by 53.7% to $57.0 million in 2023, then crashed by 93.71% to $3.6 million in 2024, then plummeted by 538.01% to -$15.7 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Common Equity are -$15.7 million (Q4 2025), -$12.3 million (Q3 2025), and -$9.0 million (Q2 2025).